Cerdulatinib gel 0.37%

cerdulatinib · Dermavant Sciences GmbH

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Cerdulatinib gel 0.37%, covering 2020-11-24 to 2020-11-24. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo [Phase 2]